/* RM 168662 - Track viewing of recorded presentations */

The Autism Biomarkers Consortium for Clinical Trials: Study Design and Progress to Interim Analysis

J. McPartland1, S. J. Webb2, F. Shic3, A. Naples1, C. Sugar4, M. Murias5, J. Dziura6, C. Brandt6, R. A. Bernier2, K. Chawarska7, G. Dawson8, S. Faja9, S. Jeste10 and C. A. Nelson11, (1)Yale Child Study Center, Yale University School of Medicine, New Haven, CT, (2)Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, (3)Center for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA, (4)University of California, Los Angeles, Los Angeles, CA, (5)Duke Center for Autism and Brain Development, Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, (6)Yale University, New Haven, CT, (7)Child Study Center, Yale University School of Medicine, New Haven, CT, (8)Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, (9)Boston Children's Hospital, Boston, MA, (10)Children's Hospital Los Angeles, Los Angeles, CA, (11)Department of Developmental Medicine, Boston Children's Hospital, Boston, MA